(Q44017442)

29 November 2017

title

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab (English)

1 reference

29 November 2017

0 references

7

Olivier Michielin

1 reference

29 November 2017

Christiane Meyer

1

1 reference

29 November 2017

Laurène Cagnon

2

1 reference

29 November 2017

Carla M Costa-Nunes

3

1 reference

29 November 2017

Petra Baumgaertner

4

1 reference

29 November 2017

Nicole Montandon

5

1 reference

29 November 2017

Loredana Leyvraz

6

1 reference

29 November 2017

Emanuela Romano

8

1 reference

29 November 2017

Daniel E Speiser

9

1 reference

29 November 2017

publication date

20 December 2013

1 reference

Cancer Immunology, Immunotherapy

29 November 2017

published in

1 reference

29 November 2017

volume

63

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

247-257

1 reference

Systematic review of medical treatment in melanoma: current status and future prospects.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Myeloid derived suppressor cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Myeloid-Derived Suppressor Cells in Human Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

The growing diversity and spectrum of action of myeloid‐derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Expression of CTLA-4 by human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

Treating Cancer by Targeting the Immune System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1508-5

10.1007/S00262-013-1508-5

21 January 2018

Identifiers

DOI

1 reference

release_utbaasekqrgltj6yvmifzqnjna

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/utbaasekqrgltj6yvmifzqnjna

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference